Amani Therapeutics, a biotech company dedicated to developing effective treatments for serious psychiatric illness, has secured $25.0M in a Series A funding round. The investment is poised to accelerate its mission of removing barriers with innovative science, aiming to deliver therapies that restore hope and stability for people living with these conditions.
The company's work focuses on enabling fuller lives for patients by addressing critical unmet needs in psychiatric care. This fresh capital will be instrumental in advancing its innovative scientific approach towards achieving these goals.















